616
Participants
Start Date
March 1, 2020
Primary Completion Date
October 31, 2024
Study Completion Date
October 31, 2024
nab paclitaxel
nab paclitaxel (120mg/m2;iv;d1,8)
Tegafur
S-1 (\<1.25 m2, 40 mg; 1.25 to ≤1.5 m2, 50 mg; and ≥ 1.5 m2, 60 mg;po;d1-14 bid)
Oxaliplatin
Oxaliplatin(130mg/m2 , iv, d1)
Capecitabine
Capetabine(1000 mg/m2 po, d1-14 bid )
RECRUITING
Zhejiang Cancer Hospital;Cancer hospital of the university of chinese academy of sciences, Hangzhou
Collaborators (1)
CSPC Ouyi Pharmaceutical Co., Ltd.
INDUSTRY
Zhejiang Cancer Hospital
OTHER